Table 1 Characteristics of included clinical trials
Characteristics | Categories | All trials (n = 473) | Investigator-sponsored trials (n = 342) | Industry-sponsored trials (n = 131) |
|---|---|---|---|---|
Target sample size in Switzerland (median, IQR) | 32 (16-75) | 45 (22-100) | 15 (8-28) | |
Trial intervention, n (%) | Drugs | 215 (45.5) | 116 (33.9) | 99 (75.6) |
Medical devices | 96 (20.3) | 69 (20.2) | 27 (20.6) | |
Behavioral | 33 (7.0) | 33 (9.6) | 0 (0.0) | |
Diagnostic | 28 (5.9) | 26 (7.6) | 2 (1.5) | |
Rehabilitation | 23 (4.9) | 23 (6.7) | 0 (0.0) | |
Dietary supplements | 18 (3.8) | 18 (5.3) | 0 (0.0) | |
Surgical | 16 (3.4) | 15 (4.4) | 1 (0.8) | |
Otherb | 44 (9.3) | 42 (12.3) | 2 (1.5) | |
Trial design, n (%) | Single arm | 121 (25.6) | 78 (22.8) | 43 (32.8) |
Multiple armsc | 352 (74.4) | 264 (77.2) | 88 (67.2) | |
Randomized | 323 (68.3) | 239 (69.9) | 84 (64.1) | |
Non randomized | 29 (6.1) | 25 (7.3) | 4 (3.1) | |
Risk categorya, n (%) | Low risk | 238 (50.3) | 220 (64.3) | 18 (13.7) |
Intermediate risk | 83 (17.6) | 71 (20.8) | 12 (9.2) | |
High risk | 152 (32.1) | 51 (14.9) | 101 (77.1) | |
Trial sites, n (%) | Single Center | 255 (53.9) | 243 (71.1) | 12 (9.2) |
Multicenter | 218 (46.1) | 99 (28.9) | 119 (90.8) | |
National | 46 (9.7) | 43 (12.6) | 3 (2.3) | |
International | 172 (36.4) | 56 (16.4) | 116 (88.5) | |
Use of CTU service, n (%) | 104 (22.0) | 104 (30.4) | 0 (0.0) | |